阿尔茨海默病中的血清能调节剂:在绝望的条件下,一个希望
Ali I Al-Gareeb1, Morkoss Fakhry2, Ali K Albuhadily3
1Jabir ibn Hayyan Medical University, surgery, Iraq, Iraq, IRAQ.
Chemistry & biodiversity
|April 1, 2025
概括
阿尔茨海默病涉及陶和粉样蛋白的积累. 向血清激素系统可能为阿尔茨海默病患者的神经退行症和相关症状提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特征是神经退行.
- 病理包括过酸化的和粉样β (Aβ) 积累,导致氧化应激和炎症.
- 目前的AD治疗不能逆转核心神经病理.
研究的目的:
- 审查血清能系统在阿尔茨海默氏症病原发生中的作用.
- 探索血清素 (5-HT) 调节器在逆转AD神经病理方面的潜力.
- 评估5-HT调节剂在治疗与阿尔茨海默病相关的神经精神疾病方面的疗效.
主要方法:
- 文献综述,重点关注血清能系统和阿尔茨海默病.
- 分析研究的分析研究色胺的合成,受体,和他们的调节失调在AD.
- 对阿兹海默症治疗中的5-HT调节器的研究进行了审查.
主要成果:
- 在阿尔茨海默病中,血清能系统显著失调.
- 血清素 (5-HT) 在抗氧化应激和炎症方面起着神经保护作用.
- 血清素合成和受体的调节失调有助于AD的发病.
结论:
- 准血清能系统是阿尔茨海默氏症治疗的有希望的治疗策略.
- 5-HT调节剂可能会逆转AD的关键神经病理特征.
- 调节血清能系统可以缓解AD患者的神经精神症状.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.2K
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
405
相关概念视频
Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
Antidepressant Drugs: MAOIs and Other Agents
170
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
170
Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
249
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
249
Parkinson's Disease: Treatment
162
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
162
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
191
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
191
